Asia-Pacific AI in Bioinformatics Market – Industry Trends and Forecast to 2029

Asia-Pacific AI in Bioinformatics Market Analysis and Size

The reduction in the genetic sequencing cost has enhanced the demand of the market. The rising healthcare expenditure for better health services is also attributed to the growth of the market. The major market players are highly focused on various service launches and service approvals during this crucial period. In addition, the growing demand for bioinformatics and increasing public-private sector funding for bioinformatics are also contributing to the rising demand for the market.

Asia-Pacific AI in bioinformatics market is growing in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. The increasing advancements in bioinformatics technology are further boosting the market growth. However, the high cost of instrumentations and cybersecurity concerns in bioinformatics might hamper the growth of the Asia-Pacific AI in bioinformatics market in the forecast period.

Data Bridge Market Research analyses that the AI in bioinformatics market is expected to reach the value of USD 4,740.88 million by 2029, at a CAGR of 37.7% during the forecast period. “Services" accounts for the largest technology segment in the AI in bioinformatics market due to rapid developments in technological pathways to commercialize the use of handheld AI in bioinformatics. The AI in bioinformatics market report also covers pricing analysis, patent analysis, and technological advancements in depth.         

Market Definition

Bioinformatics is a sub-discipline that has to do with the analysis of sequences of biological molecules. It usually refers to genes, DNA, RNA, or protein and is particularly useful in comparing genes, and other sequences in proteins and different sequences within an organism or between organisms, looking at the evolutionary relationships between organisms and using the patterns that exist across DNA and protein sequences to figure out what their function is.

Bioinformatics combines computer programming, big data, and molecular biology, which enables scientists to understand and identify patterns in biological data. It is particularly useful in studying genomes and DNA sequencing, as it allows scientists to organize large amounts of data.

From genetics to toxicology to mycology and radiobiology, there are scores of branches of biology to specialize in. And out of the many, bioinformatics is one of the intriguing fields which enables you to identify, evaluate, store, and retrieve biological information. Being an interdisciplinary field of study, it incorporates various applications of computer science, statistics, and biology to develop software applications for understanding biological data like DNA sequencing, protein analysis, evolutionary genetics, and others.

In the coming future, important decisions related to bioinformatics on drug discovery will be made by individuals who not only understand biology but can also use the bioinformatics tools and the knowledge they release to develop hypotheses and identify the quality target.

AI in Bioinformatics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:

• Growing demand for bioinformatics

As genomics focused pharmacology continues to play a greater role in the treatment of various chronic diseases, especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at the molecular underpinnings of individual tumors and specific receptors. Informatics is essential in biological research, which involves biologists who learn programming, computer programmers, mathematicians, or database managers to learn the foundations of biology.

• Reduction in the genetic sequencing cost

The strong demand for decreasing the cost of genomics and biomarker prediction has contributed to the creation of high-throughput genome sequencing, which often goes by the name next-generation sequencing (NGS). Thousands or millions of sequences in a single bioinformatics cycle are generated simultaneously. Dramatic upgrades to industrial NGS technologies have culminated in dramatic cutbacks in DNA sequencing cost-per-base. Thus recently, the main sequencing techniques have become the key subject of research, with sample design optimization taking a secondary function.

• Increasing public-private sector funding for bioinformatics

In order to improve the workflow for bioinformatics, the federal agencies, the public, and the private agencies are providing funds in order to carry out bioinformatics projects and to scientists for research purposes. It is important to approach possible funders with a clear proposal and strategy of what is to be achieved in terms of bioinformatics capacity building in the institution as well as the intended outputs and outcomes. Many government bodies and private organizations across the globe are increasingly investing in the field of bioinformatics. These investments have largely resulted in data and technological advancements in bioinformatics services, which in return, have improved the quality of these services.

• High cost of instrumentation

The cost of the device plays a major factor in the market. The AI based bioinformatics instrument is highly sophisticated, need high validation, and other specification increase. Genomics instruments are also equipped with advanced features and functionalities and are priced at a premium, ranging between USD 10–20 million. As pharmaceutical companies and research laboratories require many such systems, their capital expenditure on procuring multiple genomic instruments is very high. In the case of small and medium-sized pharmaceutical companies and research laboratories, it is not feasible for them to make such high investments in multiple genomics instruments. Hence, the high cost of AI based equipment is expected to restrain the market growth.

• Strategic initiatives of key players

The dramatic rise in the quality of research coupled with increasing research opportunities is because of various strategic initiatives taken by key market players. They are taking initiatives such as product launches, collaborations, mergers, acquisitions, and many more over the years and are expected to lead and create more opportunities in the market.

By successfully working with new technology firms to ensure continued growth, creativity, and viability in the industry, healthcare product suppliers have a huge opportunity. Health enterprises that implement technology-enabled technologies will explore new modes of goods for patient care, streamline processes, and engage patients more.

To discover and develop advanced bioinformatics products, companies are launching new initiatives, and collaborating with other key players to deliver more reliable results and services.

• Advancement in bioinformatics technology

The dimensions and cost of bioinformatics platforms and instruments are decreasing, allowing easier uptake by public health laboratories. Although currently, AI based bioinformatics requires highly specialized equipment and substantially skilled staff to analyze the data, it is unlikely that the bioinformatics revolution has finished. With rising technology upgradation of instruments and techniques is also needed, moreover, the bioinformatics market has a vast potential to upgrade in various applications, and there are high chances of the advancement of bioinformatics techniques in the forecasted period.

• Lack of skilled professionals to perform AI based bioinformatics technology

One of biology's most rapidly developing fields of study is bioinformatics, which involves the development and use of computational tools for the collection, archiving, organisation, analysis, and visualisation of biological data. The advancement of technology has made it possible to reach the level of next-generation analysis from conventional data analysis methods. The advancement of the technology of bioinformatics requires various skill sets for its handling. As the bioinformatics platforms are highly automated and costly machines, the improper handling of such machines can damage their parts which can hamper achieving analysis and visualisation of biological data. Thereby, it will proportionally hamper the result of data processing. The dearth of skilled professionals having adequate skills and knowledge to perform next-generation sequencing, therefore, hampers the growth of the market.

Post COVID-19 Impact on AI in Bioinformatics Market

During the pandemic, the bioinformatics sector is one that focused on using the combination of biology and information technology. At the heart of the industry is biological data, which is analyzed and transformed using IT techniques. Bioinformatics has always had huge potential when it comes to providing essential support to many areas of scientific research. The tools that bioinformatics can provide allow scientists to get to grips with larger data sets to mine and analyses them to discover crucial information that could lead to key discoveries. genetics and genomes have been the primary focus of bioinformatics in recent years, including comparative genomics, DNA microarrays, and functional genomics.

The growth of the AI in bioinformatics market is increasing with the growing demand for analysis tools in drug discovery and development and the integration of AI in various fields to interpret the data more conveniently. Hence, the market is expected to grow significantly in the forecast period, whereas the cost and the complexity of AI integration may hamper the market growth. The intervention of COVID-19 has increased the R&D activities, which in turn positively add to the market growth.

Recent Developments

• In June 2022, SOPHiA GENETICS, a leader in data-driven medicine, announced from the ESHG Conference in Vienna that it has achieved CE-IVD certification for the analytical functionality supported by its cloud-based SOPHiA DDM™ Platform, an accessory to diagnostic applications. With this certification, the SOPHiA DDM™ Platform is now IVD-ready to support all applications and modules designed for diagnostic purposes in the European Union and other markets recognizing this certification. This has helped the company to increase its Asia-Pacific presence in the market.
• In December 2021, JADBio and BioLizard announced their partnership. BioLizard is agile bioinformatics and AI/ML company Asia-Pacifically servicing clients in the life sciences, biotechnology, and pharmaceutical industries. JADBio is a robust automated machine learning platform that allows intuitive, timely, and interactive creation of ML predictive models on BioMedical and Multi-omics data while allowing for knowledge (biomarker signature) discovery through its vast range of reporting and analysis. This has helped the company to expand its products and services portfolio in the market.

Asia-Pacific AI in bioinformatics Market Scope

Asia-Pacific AI in bioinformatics market is segmented on the basis of offering, type, products and services, application, and sector. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Offering

• Services
•  Software
•  Others

On the basis of offering, the Asia-Pacific AI in bioinformatics market is segmented into services, software, and others.

Type

• Machine Learning
• Deep Learning
• Others

On the basis of type, the Asia-Pacific AI in bioinformatics market has been segmented into machine learning, deep learning, and others.

Products and Services

• Bioinformatics Services
• Bioinformatics Platforms
• Knowledge Management Tools

On the basis of products and services, the Asia-Pacific AI in bioinformatics market has been segmented into bioinformatics services, bioinformatics platforms, and knowledge management tools.

Application

• Genomics
• Chemoinformatics & Drug Design
• Proteomics
• DNA Sequencing
• System Biology
• Transcriptomics
• Text Mining
• Microarrays
• Metabolomics
• Others

On the basis of application, the Asia-Pacific AI in bioinformatics market has been segmented into below genomics, chemoinformatics & drug design, proteomics, DNA sequencing, system biology, transcriptomics, text mining, microarrays, metabolomics and others.

Sector

• Medical Biotechnology
• Animal Biotechnology
• Plant Biotechnology
• Environmental Biotechnology
• Forensic Biotechnology
• Others

On the basis of sector, the Asia-Pacific AI in bioinformatics market has been segmented into medical biotechnology, animal biotechnology, plant biotechnology, environmental biotechnology, forensic biotechnology, and others.

AI in Bioinformatics Market Regional Analysis/Insights

The AI in bioinformatics market is analysed, and market size insights and trends are provided by country, offering, type, products and services, application, and the sector as referenced above.

The countries covered in the Asia-Pacific AI in bioinformatics market report are China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific. China is expected to dominate the Asia-Pacific AI in bioinformatics market due to the rising demand for advanced technology in bioinformatics for drug discovery, and genomics, among others. However, the complexity of understanding AI and its development is expected to hinder the market growth in the forecast period.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.

China is expected to dominate the Asia-pacific AI in bioinformatics market due to the rise in technological advancement in the AI and the rise in integration of AI in various fields. China is followed by Japan due to the rise in technological advancements in the country, and South Korea is attributed to the fact of rising in drug discovery and development demands and rise in clinical trials.

Competitive Landscape and AI in bioinformatics Market Share Analysis

The AI in bioinformatics market competitive landscape provides details about the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the company’s focus on the AI in bioinformatics market.

Some of the major players operating in the AI in bioinformatics market are SOPHiA GENETICS, Biomax Informatics Inc., QIAGEN, NeoGenomics Laboratories, Eurofins Scientific, Illumina, Inc., Thermo Fisher Scientific, Inc., Strand Life Sciences, Dassault Systèmes, SomaLogic Operating Co., Inc., Elucidata among others.

SKU-69030